Tonghua Dongbao Pharmaceutical Co Ltd (600867.SS) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE000000H87
Tonghua Dongbao Pharmaceutical Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.01 bn CNY | 2.95 bn CNY |
| Gross profit | 1.46 bn CNY | 2.07 bn CNY |
| Operating income | 168.18 m CNY | 602.84 m CNY |
| EBIT | -128.91 m CNY | 1.50 bn CNY |
| Net income | -42.72 m CNY | 1.22 bn CNY |
| Diluted EPS – continuing operations | -0.02 CNY | 0.62 CNY |
Full history since 1994, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Tonghua Dongbao Pharmaceutical Co Ltd
Tonghua Dongbao Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of biological products, traditional Chinese medicines, chemical medicines, and other drugs in China and internationally. The company offers liraglutide injections; insulin glargine injections; insulin aspart injections; human insulin injections; isophane protamine human insulin injections; mixed protamine human insulin injections; suganning capsules; pediatric paracetamol and artificial cow-bezoar and chlorphenamine maleate granules; zhennaoning capsules; compound methionine and choline bitartrate tablets; and compound kushen changyankang tablets. It also provides insulin pens and pen needles; and the Chronic Disease Management Platform, which is a diabetes management platform for drug treatment, blood glucose monitoring, and patient education. In addition, the company offers oral anti-diabetic hypoglycemic drugs, such as sitagliptin phosphate, sitagliptin phosphate/metformin hydrochloride, repaglinide, and engagliflozin tablets. Further, it engages in the manufacture, sale, and servicing of plastic building materials and products; technology development of biological products and natural medicines; leasing of workshops; real estate development and sales; second-hand housing transactions; provision of biopharmaceuticals; medical research and experimental development; pharmaceutical retail and wholesale; technical services, technology development, and technical consulting; operation of medical devices and food products; import and export of goods and technologies; internet sales; and health and consulting services. Tonghua Dongbao Pharmaceutical Co., Ltd. was founded in 1985 and is headquartered in Tonghua, China.
More stocks
- Northwest Bancshares, Inc. (NWBI)
- Chicony Electronics Co Ltd (2385.TW)
- Gossamer Bio, Inc. (GOSS)
- OC Oerlikon Corporation AG Pfaeffikon (OERL.SW)
- AF Gruppen ASA (AFG.OL)
- Addus HomeCare Corp (ADUS)
- Shanghai Suochen Information Technology Co. Ltd. A (688507.SS)
- Shenyang Jinshan Energy Co Ltd (600396.SS)
- Regional S.A.B. de C.V (RA.MX)
- Xencor Inc (XNCR)
- Jiayou International Logistics Co Ltd (603871.SS)
- Wuhu Token Sciences (300088.SZ)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.